Spero Therapeutics Q4 2024 Earnings Report

Spero Therapeutics EPS Results

• Actual EPS: -$0.38
• Consensus EPS: -$0.35
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Spero Therapeutics Revenue Results

• Actual Revenue: $15.04 million
• Expected Revenue: $12.40 million
• Beat/Miss: Beat by +$2.64 million
• YoY Revenue Growth: N/A

Spero Therapeutics Announcement Details

• Quarter: Q4 2024
• Date: 3/27/2025
• Time: After Market Closes

Spero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.